anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present disclosure relates to an accessory device ( 8 ). The accessory device is configured to communicate with an ostomy system. The ostomy system comprises a monitor device, and/or an ostomy appliance configured to be placed on a skin surface of a user. The ostomy appliance comprises abase plate. The accessory device comprises: a processor ( 402 ); a memory ( 401 ); and an interface ( 403 ) operatively connected to the processor and the memory. The interface is configured to obtain monitor data from the monitor device. The processor is configured to determine a current operating state of the ostomy appliance and a future operating state of the ostomy appliance based on the monitor data. The current operating state is indicative of adhesive performance of the ostomy appliance, wherein the future operating state is indicative of the adhesive performance of the ostomy appliance. The interface is configured to communicate the current operating state and the future operating state.
The Combat Bladder Recirculation System (BRS) is a CE marked device which has been used in over 200 sites in Europe. It is an aluminum heat exchanger that allows hyperthermic intravesical chemotherapy (HIVEC) at 43±0.2 degrees for patients with bladder cancer. Previous studies showed that the Combat BRS could warm the entire bladder wall to the target temperature with excellent safety parameters. The flow rates and pressure levels are kept low during the HIVEC treatment. A previous study has demonstrated the safety and tolerability of HIVEC as a maintenance therapy for patients with non-muscle-invasive bladder cancer (NMIBC), and two randomized controlled trials are underway to demonstrate its efficacy in terms of disease recurrence and progression. On the other hand, the use of HIVEC immediately following transurethral resection of bladder tumour (TURBT) remains largely unexplored. It is the investigators' current practice to give intravesical mitomycin C (MMC) to all patients who have endoscopically NMIBC with complete resection, provided that there are no bladder perforations being noted. In this study, the investigators shall evaluate the safety and feasibility of hyperthermia in addition to the current practice of intravesical MMC alone immediately following TURBT.
The experimental intervention is early implantation of a left ventricular assist device (early VAD). Patients randomized to early VAD implantation will obtain a VAD within 28 days after randomization.
OBJECTIVES: To report the long-term outcomes of patients with type B aortic dissection (TBAD) treated with thoracic endovascular aortic repair (TEVAR) and quick fenestrated (QF)-assisted in situ fenestration (ISF).
METHODS: Between October 2017 and December 2018, 15 patients with TBAD requiring revascularization of the supra-aortic trunks underwent TEVAR with QF-assisted ISF at our institution.
RESULTS: Thirteen of the 15 patients were male, and the mean age was 52.87 ± 11.26. The technical success rate was 100%. Thirty-day mortality rate was 0. The median follow-up period was 41 months (range, 35-49). During follow-up, one non-aortic-related death was recorded, no fenestration lost its alignment, and no stroke or stent graft migration was observed. Two patients underwent another successful endovascular repair. One case of type Ib endoleak occurred 19 months postoperatively. This was caused by aortic progression distal to the stent graft. Another stent graft with a larger diameter was implanted in the descending aorta. One case of type Ic endoleak was observed 35 months postoperatively. The patient was diagnosed during the annual follow-up without any symptoms. Another bridging stent graft was implanted into the left subclavian artery distal to the already existing one, and the type Ic endoleak was successfully treated.
CONCLUSIONS: TEVAR with QF-assisted ISF may be an effective treatment for ISF in type B aortic dissection.
The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as a primary cutaneous lymphoma which may be a cutaneous T cell lymphoma (CTCL). The CTCL may be mycosis fungoides, primary cutaneous anaplastic large cell lymphoma (ALCL), or Sezary syndrome. A patient may be administered a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene).
PURPOSE:A liquid or granular bath agent, obtained by extracting powder prepared by oxidizing vegetable humic mud and finely pulverizing the oxidized mud with water or granulating the powder into granules, and having effect of astringent/blood circulation promoting action as the bath agent and further turbidity flocculation/deodorant action. CONSTITUTION:A liquid or granular bath agent obtained by extracting powder prepared by oxidizing vegetable humic mud, and finely pulverizing the oxidized mud with water or granulating the powder into granules. The above-mentioned aqueous extract and granules are well known respectively as Humus erurabin and Humus gardoran (both are tradenames), and the former is directly put into hot water at about 0.5l/bathtub for one person. The latter contained in an adequate amount is put into a cloth bag and dipped in hot water. Thus, the agent produces effect of moderate astringent action, blood circulation promoting action, etc., as the bath agent on the skin, and further eliminates turbidity or odor by the flocculating action and deodorant action. Baths can be taken pleasantly for any length of time.
PURPOSE:To provide an antienzyme containing 3,5-diisopropyl-4-hydroxy-styrene derivative or its salt as an active component, having inhibiting action to tyrosine kinase participating in the control of cell proliferation and useful as a carcinostatic agent and anticarcinogenetic agent. CONSTITUTION:A tyrosine kinase inhibiting agent can be produced by using the compound of formula (R<1> is H, CN or amido; R<2> is amido or CONHCONH2) or its physiologically permissible salt as an active component. The concrete example of the compound of formula is 3,5-diisopropyl-4-hydroxycinnamic acid amide, etc. The compound of formula is effective to inhibit tyrosine kinase and can be used as a carcinostatic agent and anticarcinogenetic agent having low side effect. The compound of formula can be produced by reacting 3,5- diisopropyl-4-hydroxybenzaldehyde with the compound of formula R<3>-CH2-R<2> (R<3> is CN, amido, etc.) in the presence of a basic catalyst.
BACKGROUND: Therapeutic phlebotomy (TP), a widely used medical procedure, can be performed on diverse patients with iron overload or polyglobulia. However, its adverse events are not well known as most of the information on phlebotomy is derived from healthy blood donors (0.1%-5.3%). In contrast, TP is applicable to a broader, more complex population with comorbidities and old age. To ascertain the incidence of adverse events in phlebotomies, we conducted a prospective study on patients who attended our Unit.
STUDY DESIGN AND METHODS: We prospectively gathered data from patients referred to our Unit for TP. Data regarding demographics, health status, and adverse events within at least 24 h of phlebotomy were gathered via a structured questionnaire during each visit.
RESULTS: Between August 2021 and September 2022, 189 patients underwent 587 procedures. Most patients were men, over 60 (57.3%) had comorbidities, and 93% underwent at least two procedures during the study period. Twenty patients (10.8%) presented 25 adverse events (4.3% of phlebotomies), usually vasovagal reactions, none of which were clinically relevant, and all were managed by nursing staff on site, with full patient recovery.
DISCUSSION: The rate of adverse events (<5%) in patients undergoing TP was low and comparable to that seen in healthy blood donors. Consequently, even old patients and those with some comorbidities can safely undergo TP when the process is carefully managed.
PURPOSE: Human papillomavirus (HPV) is the most commonly transmitted sexually transmitted infection. HPV infections have been on the rise among males, especially in the form of oropharyngeal cancer. Despite this, there is a gap in healthcare guidelines to increase HPV vaccine administration among males. In this study, we focus on the Indigenous population of North America and Oceania to determine existing barriers resulting in low HPV vaccination rates among the population.
METHOD: We surveyed peer-reviewed literature on the awareness of HPV infection among Indigenous males in North America and Oceania. Using keywords HPV plus male, men or boy, and ethnical filters such as Indigenous, Aboriginal or First Nations, we retrieved 54 articles based on titles, of which 15 were included after reading the abstracts.
RESULTS: Reported HPV awareness was generally low in Indigenous males in North America, with no peer-reviewed data from Oceania. The lower understanding by males compared to females was largely attributable to misconceptions about HPV-related diseases, their transmission, and prevention. Lack of awareness and concern toward the risk of contracting HPV infection in Indigenous males suggests an impediment in disseminating health information about this cancer-causing virus.
CONCLUSION: Culturally sensitive education, with emphasis on Indigenous males, is needed to improve this group's HPV knowledge. Researchers should also engage meaningfully with Indigenous communities by building rapport to achieve a positive change in attitude.
Participants in this group will complete 3 resistance training sessions per week for 6 weeks (18 sessions total). During each training session, participants will perform 3 sets of bilateral leg-extensions (performed with both legs) to volitional failure using 30% of their 1-repetition maximum (the most weight they are able to perform 1 complete repetition with, but not 2). Participants in this group will perform all leg extensions with blood flow restriction cuffs applied to the proximal thigh of both legs. The pressure that the cuffs are inflated to will be calculated based on estimates of each subject's arterial occlusion pressure from their thigh circumference. Once the target pressure is reached, the cuffs will not be deflated until after the final set of the training session.
Triple combination therapy with pembrolizumab plus preliminary RP2D A of MK-4830 plus paclitaxel in participants who have histologically confirmed, ovarian cancer. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1 for a maximum of 35 cycles (up to approximately 2 years). Each cycle is 21 days. Paclitaxel will be administered by IV, once every week (QW) on Days 1, 8, and 15 of each 21-day cycle until disease progression or prohibitive toxicity.
In combination with conventional therapies (e.g., targeted therapy, chemotherapy, and angiogenesis inhibitors etc.), immunotherapies targeting checkpoint molecules have shown promise in the treatment of solid or liquid tumors. However, apoptotic regulatory T cells (Treg) induced by such therapies often become more suppressive in the tumor microenvironment (TME), through increased generation of adenosine tightly controlled by ectonucleotidases, viz. CD39 and CD73. CD39/ENTPD1, a novel checkpoint molecule, is highly expressed and activated on the tumor vasculature and infiltrating immune cells, promoting tumor growth. Deletion or blockade of CD39 enhances anti-tumor activity by augmenting anti-tumor immune responses and inhibiting tumor angiogenesis. The present invention is based at least in part on the development of anti-CD39 antibodies which mediate CD39 downregulation on immune cells, such as T-cells with markers of T-cell exhaustion, and the demonstrated utility of these antibodies in blocking tumor growth with minimal side effects in pre-clinical models.
CHIMPS-P is a family-oriented prevention for children and adolescents without signs of mental disorders in the initial screening. These families will receive the 3 family sessions from the modular CHIMPS intervention. The sessions will be carried out by a social worker (based on the Finnish model "Let's talk about children (Solantaus), but in a family setting "Let's talk WITH children").
Despite operating in clean theaters, surface sterilization, and antibiotics, surgical site infections (SSI) after orthopaedic surgery have an estimated incidence of 1-4%. This feared complication is associated with long-term antibiotics, repeated surgeries, prolonged hospital stays, economic burden and a poorer end result for individual patients. It is therefore of great importance to prevent SSI.While skin bacteria and contaminated surfaces have generally been claimed to be the main cause of infections, there are estimates that approximately 20% of hospital-acquired infections are air-transmitted, making this an interesting intervention target. Novaerus is an air-cleaner that sterilizes the air particles through a plasma chamber. Air in the operating theatre is pumped through the chamber (80-380 m3/Hr) and by using a small current it transforms the gas in the vicinity of the electrode into plasmaand eradicates any bacteria that pass through.The small size of the machine allows it to fit into any operating theater without interfering with existing equipment. This technology can reduce the number of colony forming units (CFU) when in hospital settings. In non-randomized settings it has been correlated to reduced respiratory infections, reduced personnel sick-leave, and absence of severe infectious outbreaks. Its effect has not been validated in randomized controlled trials. Both local and national registry data will be used according to availability.
In this study, the Inventors report that CD9 is a key component of PC-associated CAFs-derived ANXA6+-EVs. They determined that CD9 is expressed by PC-associated CAFs in vitro as well as in vivo. Targeting CD9 impaired CAFs-derived ANXA6+-EVs uptake by pancreatic cancer cells, which consequently decreases their migratory abilities. Signaling pathway arrays highlighted p38/MAPK as activated in pancreatic cancer cells following CAFs-derived ANXA6+/CD9+-EVs uptake. The use of CD9 blocking antibody, p38 siRNA or chemical inhibitors impaired pancreatic cancer cells abilities following incubation with CAFs-derived ANXA6+/CD9+-EVs. Finally, they revealed CD9 expression as an independent poor-prognosis marker in human PC samples. Collectively their data highlight the key role of CD9 in CAFs-derived ANXA6+-EVs internalization by pancreatic cancer cells and the consequent, and mandatory, activation of p38/MAPK pathway to foster their migratory abilities. Measuring the oncogenic CAFs-derived ANXA6+/CD9+-EVs then limiting their action on pancreatic cancer cells abilities might be a promising option for PC stratification and treatment.
FIELD: organic chemistry and technology, pharmacy. SUBSTANCE: invention relates to 2-cyano-3-hydroxypropeneamides of the formula (I)   where each of A, B and E means =CH-group or nitrogen atom; R is C 3 -C 6 -cycloalkyl; R 1  is hydrogen; R 2  and R 3  are similar or distinct - hydrogen, C 1 -C 6 -alkyl, trifluoromethyl, halogen, nitro-group. Invention relates to also methods of synthesis of compounds of the formula (I). The 1-st method: compound of the formula (II)   is subjected for interaction with sodium hydride and then with functional derivatives of an acid of the formula Hal-C(O)-R A  where Hal is halogen atom; R A  has values R or they are R-protected radical. The synthesized compound of the formula (IA)   is isolated after protecting group removal if necessary. The 2-d method: compounds of the formula (IV)   are subjected for interaction with a strong base. Invention relates to a pharmaceutical composition containing a compound of the formula (I) taken at effective amount and exhibiting an antiinflammatory activity. EFFECT: improved methods of synthesis, enhanced effectiveness of compounds. 9 cl, 2 tbl, 10 ex
Participants will receive an MRI with a 1 cm diameter plastic ball that contains 13C-urea that acts as test object. It provides a signal that is used to ensure that the MRI system is functioning properly.
Face-to-Face Group: At the beginning of the session self-efficacy will be measured. This group will receive an instructor-led 45 minute long lecture on how to evaluate work, love, and play behavioral health form on a standardized patient. A face-to- face standardized patient scenario will test the participant on the application of work, love, and play assessment. In this scenario, the participant will meet a standardized patient in the exam room to discuss a behavioral health concern. At the end of each session (approximately 2 hours later), self-efficacy will be measured.
The recommended dose of ProAmatine® is 10 mg, 3 times daily. Dosing should take place during the daytime hours when the patient needs to be upright, pursuing the activities of daily living. A suggested dosing schedule of approximately 4-hour intervals is as follows: shortly before, or upon arising in the morning, midday and late afternoon (not later than 6 P.M.). Doses may be given in 3-hour intervals, if required, to control symptoms, but not more frequently. Single doses as high as 20 mg have been given to patients, but severe and persistent systolic supine hypertension occurs at a high rate (about 45%) at this dose. In order to reduce the potential for supine hypertension during sleep, ProAmatine® should not be given after the evening meal or less than 4 hours before bedtime. Total daily doses greater than 30 mg have been tolerated by some patients, but their safety and usefulness have not been studied systematically or established. Because of the risk of supine hypertension, ProAmatine® should be continued only in patients who appear to attain symptomatic improvement during initial treatment.

The supine and standing blood pressure should be monitored regularly, and the administration of ProAmatine® should be stopped if supine blood pressure increases excessively.

Because desglymidodrine is excreted renally, dosing in patients with abnormal renal function should be cautious; although this has not been systematically studied, it is recommended that treatment of these patients be initiated using 2.5-mg doses.

Dosing in children has not been adequately studied. 

Blood levels of midodrine and desglymidodrine were similar when comparing levels in patients 65 or older vs. younger than 65 and when comparing males vs. females, suggesting dose modifications for these groups are not necessary.
The study is comprised of 3 dose cohorts and two dose escalation steps \[Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants\]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
OBJECTIVE: To evaluate the feasibility of prophylactic radiofrequency isolation of the pulmonary veins, with left atrial appendage amputation, to reduce the incidence of postoperative atrial fibrillation after cardiac surgery in patients aged 70 years and older.
METHODS: The Federal Food and Drug Administration granted an investigational device exemption to utilize a bipolar radiofrequency clamp for prophylactic pulmonary vein isolation in a limited feasibility trial. Sixty-two patients without prior dysrhythmias were prospectively randomized to undergo either their index cardiac surgical procedure or bilateral pulmonary vein isolation and left atrial appendage amputation during their cardiac operation. The primary outcome was occurrence of in-hospital postoperative atrial fibrillation. Subjects were on 24-hour telemetry until discharge. Dysrhythmias, any episode of atrial fibrillation >30 seconds, were confirmed by electrophysiologists blinded to the study.
RESULTS: Sixty patients, mean age 75 years and mean Congestive heart failure, Hypertension, Age (>65 = 1, >75 = 2 points), Diabetes, previous Stroke/Transient ischemic attack (2 points), Vascular disease, Gender (female) score of 4, were analyzed. Thirty-one patients randomized to control and 29 to the treatment group. The majority of patients in each group underwent isolated coronary artery bypass grafting. No perioperative complications related to the treatment procedure, need for permanent pacemaker, or mortality occurred. The in-hospital incidence of postoperative atrial fibrillation was 55% (17 out of 31) in the control group and 7% (2 out of 29) in the treatment group (P < .001) The control group had a significantly higher requirement for antiarrhythmic medications at discharge: 45% (14 out of 31) versus 7% (2 out of 29) in the treatment group (P < .001).
CONCLUSIONS: Prophylactic radiofrequency isolation of the pulmonary veins with left atrial appendage amputation during the primary cardiac surgical operation reduced the incidence of postoperative atrial fibrillation in patients aged 70 years and older with no history of atrial arrhythmias.
The invention provides construction and application of chimeric antigen receptor NK cells targeting CLL-1 and NKG2D ligands, wherein the chimeric antigen targeting the CLL-1 and the NKG2D ligands has the amino acid sequence of SEQ ID NO. 5 and a nucleotide fragment encoding the chimeric antigen, and one sequence of the chimeric antigen targeting the CLL-1 and the NKG2D ligands is SEQ ID NO. 6. The chimeric antigen targeting CLL-1 and NKG2DL is obtained by a total gene synthesis technology, and is inserted into a pLVX-IRES-Neo lentiviral expression vector to obtain a recombinant plasmid; packaging of lentiviruses using 293T cells; and (3) sorting PBMC in peripheral blood by using magnetic beads to obtain NK cells, adding cytokines to activate the NK cells, and adding lentivirus to the NK cells amplified to the 6 th day to obtain the CAR-NK cells. Co-culturing the CAR-NK cells and tumor cells positively expressed by the NKG2D ligand, and detecting the killing effect of the CAR-NK cells on the tumor cells in a flow mode. The results of the invention show that the constructed CAR-NK cells targeting CLL-1 and NKG2DL can be applied to the treatment of acute myeloid leukemia.
We anticipate the control condition will contain the following: the enhanced treatment as usual (ETAU; n=30) will consist of PWH receiving treatment at their HIV primary care clinic as usual, enhanced by supplemental food parcels and referrals for mental health care and food service organizations. Treatment as usual for mental health care is evaluation by a nurse and referral to a medical officer or to a traveling psychologist available 1 day per week. Because there is no standard of care for food insecurity, we propose that all participants will receive food parcels, but ETAU participants will not receive case management or psychosocial intervention.